PMID- 28693262
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Jul
TI  - AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR 
      signaling pathway.
PG  - 981-986
LID - 10.3892/ol.2017.6214 [doi]
AB  - Axis inhibition protein 1 (AXIN1) is characterized as a tumor suppressor in 
      numerous types of cancer. However, the functional role of AXIN1 in the testicular 
      germ cell tumors (TGCTs) remains unclear. The human embryonal carcinoma-derived 
      cell line NTera2 was transfected with a recombinant AXIN1 expression vector 
      (pcDNA3.1-AXIN1) and/or a small interfering RNA (siRNA) directed against AXIN1 
      (siAXIN). Following transfection, the mRNA and protein levels of AXIN1 were 
      determined via reverse transcription-quantitative polymerase chain reaction 
      analysis and western blotting, respectively. In addition, cell viability, 
      apoptosis and the expression of apoptosis-associated proteins [apoptosis 
      regulator Bax (Bax) and B-cell lymphoma (Bcl)-2] and phosphatidylinositol 
      3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) 
      signaling pathway proteins [phosphorylated (p)-mTOR, mTOR, p-AKT, AKT, P-70S 
      ribosomal protein S6 (S6) and S6] were assessed. AXIN1 mRNA and protein levels 
      were increased following transfection with pcDNA3.1-AXIN1 and decreased following 
      transfection with siAXIN1 compared with their respective control groups. After 
      overexpression of AXIN1, NTera2 cell viability and expression of Bcl-2, p-mTOR 
      p-AKT and p-S6 protein was decreased, while apoptosis and Bax protein levels were 
      increased, compared with the control group. However, there was no significant 
      difference in AXIN1 mRNA expression, apoptosis or Bax/Bcl-2 protein expression 
      when NTera2 cells were simultaneously transfected with pcDNA3.1-AXIN1+siAXIN1. In 
      conclusion, the results of the present study indicate that overexpression of 
      AXIN1 protects against TGCTs via inhibiting the PI3K/AKT/mTOR signaling pathway, 
      suggesting that AXIN1 may be a potential target for gene therapy in TGCTs.
FAU - Xu, Hailiang
AU  - Xu H
AD  - Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, 
      Henan 463000, P.R. China.
FAU - Feng, Yunyun
AU  - Feng Y
AD  - Department of Pediatrics, The Zhumadian City Center Hospital, Zhumadian, Henan 
      463000, P.R. China.
FAU - Jia, Zhankui
AU  - Jia Z
AD  - Department of Urinary Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan 450000, P.R. China.
FAU - Yang, Jinjian
AU  - Yang J
AD  - Department of Urinary Surgery, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan 450000, P.R. China.
FAU - Lu, Xueren
AU  - Lu X
AD  - Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, 
      Henan 463000, P.R. China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, 
      Henan 463000, P.R. China.
FAU - Xia, Mingliang
AU  - Xia M
AD  - Department of Urinary Surgery, The Zhumadian City Center Hospital, Zhumadian, 
      Henan 463000, P.R. China.
FAU - Wu, Chunru
AU  - Wu C
AD  - Department of Gynecology, The Zhumadian City Center Hospital, Zhumadian, Henan 
      463000, P.R. China.
FAU - Zhang, Yonggang
AU  - Zhang Y
AD  - Department of Emergency, The Zhumadian City Center Hospital, Zhumadian, Henan 
      463000, P.R. China.
FAU - Chen, Jianhua
AU  - Chen J
AD  - Department of General Surgery, The Zhumadian City Center Hospital, Zhumadian, 
      Henan 463000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20170519
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5494680
OTO - NOTNLM
OT  - PI3K/AKT/mTOR signaling pathway
OT  - axis inhibition protein 1
OT  - testicular germ cell tumors
EDAT- 2017/07/12 06:00
MHDA- 2017/07/12 06:01
PMCR- 2017/05/19
CRDT- 2017/07/12 06:00
PHST- 2015/09/21 00:00 [received]
PHST- 2017/02/27 00:00 [accepted]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/07/12 06:01 [medline]
PHST- 2017/05/19 00:00 [pmc-release]
AID - OL-0-0-6214 [pii]
AID - 10.3892/ol.2017.6214 [doi]
PST - ppublish
SO  - Oncol Lett. 2017 Jul;14(1):981-986. doi: 10.3892/ol.2017.6214. Epub 2017 May 19.